Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 559-568

  Mitchell, Gabriel ^a   Lafrance, Myriame ^a   Boulanger, Simon ^a   Séguin, David Lalonde ^a   Guay, Isabelle ^a   Gattuso, Mariza ^a   Marsault, Éric ^b   Bouarab, Kamal ^a   Malouin, François ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Aminoglycoside resistant staphylococci; Antibiotic synergy; Cystic fibrosis; Mrsa; Steroidal alkaloids

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; OXACILLIN; PLANT MEDICINAL PRODUCT; STREPTOMYCIN; TETRACYCLINE; TOBRAMYCIN; TOMATIDINE; TOMATINE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SPECIFICITY; ESCHERICHIA COLI; GENE EXPRESSION; GROWTH INHIBITION; HEMOLYSIS; HUMAN; HUMAN TISSUE; NONHUMAN; PHARMACOLOGICAL BLOCKING; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS SAPROPHYTICUS;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ERYTHROCYTES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HEMOLYSIN PROTEINS; HEMOLYSIS; HORSES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; REAL-TIME POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TOMATINE; VIRULENCE; VIRULENCE FACTORS;

EID: 84856973352     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr510     Document Type: Article

References (52)

1. Shah PM. The need for new therapeutic agents: what is the pipeline? Clin Microbiol Infect 2005; 11 Suppl 3: 36-42.
2. Talbot GH, Bradley J, Edwards JE Jr et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
3. Witte W, Cuny C, Klare I et al. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol 2008; 298: 365-77.
4. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179-81.
5. Casey AL, Lambert PA, Elliott TS. Staphylococci. Int J Antimicrob Agents 2007; 29 Suppl 3: S23-32.
6. Goerke C, Wolz C. Regulatory and genomic plasticity of Staphylococcus aureus during persistent colonization and infection. Int J Med Microbiol 2004; 294: 195-202.
7. Canadian Cystic Fibrosis Foundation Patient Data Registry Report 2009. http://www.cysticfibrosis.ca/assets/files/pdf/CPDR_ReportE.pdf (27 October 2011, date last accessed).
8. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2009. http://www.cff.org/UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf (27 October 2011, date last accessed).
9. European Cystic Fibrosis Society Patient Registry Report 2007 Data. http://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFRreport2007final.pdf (27 October 2011, date last accessed).
10. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194-222.
11. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2010; 65: 1853-61.
12. Chambers HF, Deleo FR.Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41.
13. Dasenbrook EC, Checkley W, Merlo CA et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303: 2386-92.
14. Dasenbrook EC, Merlo CA, Diener-West M et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-21.
15. Leonard FC, Markey BK. Meticillin-resistant Staphylococcus aureus in animals: a review. Vet J 2008; 175: 27-36.
16. Garci{dotless}́a-Álvarez L, Holden MT, Lindsay H et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis 2011; 11: 595-603.
17. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48: 1429-49.
18. Novick RP, Geisinger E. Quorum sensing in staphylococci. Annu Rev Genet 2008; 42: 541-64.
19. González-Lamothe R, Mitchell G, Gattuso M et al. Plant antimicrobial agents and their effects on plant and human pathogens. Int J Mol Sci 2009; 10: 3400-19.
20. Mitchell G, Gattuso M, Grondin G et al. Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2011; 55: 1937-45.
21. Niño J, Correa YM, Mosquera OM. Biological activities of steroidal alkaloids isolated fromSolanum leucocarpum. Pharm Biol 2009; 47: 255-9.
22. Proctor RA, von Eiff C, Kahl BC et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305.
23. Kahl BC, Duebbers A, Lubritz G et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003; 41: 4424-7.
24. Tuchscherr L, Medina E, Hussain M et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3: 129-41.
25. Diarra MS, Petitclerc D, Lacasse P. Response of Staphylococcus aureus isolates from bovine mastitis to exogenous iron sources. J Dairy Sci 2002; 85: 2141-8.
26. Moisan H, Brouillette E, Jacob CL et al. Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J Bacteriol 2006; 188: 64-76.
27. Horsburgh MJ, Aish JL, White IJ et al. sB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325-4. J Bacteriol 2002; 184: 5457-67.
28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
29. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore, MD: Williams and Wilkins, 1996; 330-6.
30. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
31. Schmitz FJ, Fluit AC, Gondolf M et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother 1999; 43: 253-9.
32. Allard M, Moisan H, Brouillette E et al. Transcriptional modulation of some Staphylococcus aureus iron-regulated genes during growth in vitro and in a tissue cage model in vivo. Microbes Infect 2006; 8: 1679-90.
33. Sampson BA, Misra R, Benson SA. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 1989; 122: 491-501.
34. Mazzariol A, Cornaglia G, Nikaido H. Contributions of the AmpC b-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to b-lactams. Antimicrob Agents Chemother 2000; 44: 1387-90.
35. Pazoles CJ, Kulpa CF Jr. Biosynthesis and structure of lipopolysaccharide in an outer membrane-defective mutant of Escherichia coli J5. Biochim Biophys Acta 1977; 466: 160-75.
36. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13: 151-71.
37. Shaw KJ, Rather PN, Hare RS et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138-63.
38. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987; 51: 341-50.
39. Miller MH, Wexler MA, Steigbigel NH. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother 1978; 14: 336-43.
40. Wilson SG, Sanders CC. Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides. Antimicrob Agents Chemother 1976; 10: 519-25.
41. Cheung AL, Chien YT, Bayer AS. Hyperproduction of a-hemolysin in a sigB mutant is associated with elevated SarA expression in Staphylococcus aureus. Infect Immun 1999; 67: 1331-7.
42. Herbert S, Ziebandt AK, Ohlsen K et al. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect Immun 2010; 78: 2877-89.
43. Lauderdale KJ, Boles BR, Cheung AL et al. Interconnections between Sigma B, agr, and proteolytic activity in Staphylococcus aureus biofilm maturation. Infect Immun 2009; 77: 1623-35.
44. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60.
45. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: 32.
46. Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med 2010; 16: 604-10.
47. Durante-Mangoni E, Grammatikos A, Utili R et al. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009; 33: 201-5.
48. Wise R. The urgent need for new antibacterial agents. J Antimicrob Chemother 2011; 66: 1939-40.
49. Balaban N, Cirioni O, Giacometti A et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 2007; 51: 2226-9.
50. Gov Y, Bitler A, Dell'Acqua G et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 2001; 22: 1609-20.
51. Lyon GJ, Mayville P, Muir TW et al. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. Proc Natl Acad Sci USA 2000; 97: 13330-5.
52. Projan SJ, Brown-Skrobot S, Schlievert PM et al. Glycerol monolaurate inhibits the production of b-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J Bacteriol 1994; 176: 4204-9.